前列腺癌中PROTACs的概念验证
Proof-of-Concept with PROTACs in Prostate Cancer.
出版信息
Cancer Discov. 2020 Aug;10(8):1084. doi: 10.1158/2159-8290.CD-NB2020-054. Epub 2020 Jun 5.
Abstract
Preliminary clinical data for ARV-110, a proteolysis-targeting chimera that flags the androgen receptor for degradation, indicate that the drug is safe and shows some efficacy in men with metastatic castration-resistant prostate cancer.
摘要
ARV-110是一种靶向蛋白水解嵌合体，可标记雄激素受体以便降解，其初步临床数据表明，该药物安全，对转移性去势抵抗性前列腺癌男性患者有一定疗效。
Zotero 插件